Antibody Programs (Oncology/Inflammatory)

About Ibex Biosciences

Ibex Biosciences is a private, pre-clinical biotech firm pursuing a multi-platform strategy in antibodies, gene therapy, and regenerative medicine. The company leverages its internal discovery capabilities, highlighted by its CSO's background in phage display technology, to build a wholly-owned pipeline targeting oncology, infectious disease, and inflammatory conditions. Currently in a pre-revenue stage, Ibex is actively seeking investment through a Regulation D 506(c) offering to advance its programs. Its management team brings decades of experience in preclinical research, gene therapy, and business development.

Therapeutic Areas